MIST Stock Analysis: Buy, Sell, or Hold?
MIST - Milestone Pharmaceuticals Inc. Common Shares
$1.92
0.03 (1.59%)
▲
5d:
+2.67%
30d:
-4.48%
90d:
+9.09%
BUY
MODERATE Confidence
Analysis Updated: May 8, 2026 12:00 AM ET
Earnings: May 13, 2026
2d
Smart Money Accumulation
MIST is down 3.7% this week, but smart money is accumulating calls. Top strike: $2 2026-06-18 with 12,245 OI. Call ratio: 91% View Scanner →
Strength: 6.0/10
Get Alerted When MIST Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called MIST this week
0% bullish • 1 bearish
0% bullish • 1 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: MIST shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: MIST shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: MIST is currently trading at $1.92, which is considered fair relative to its 30-day fair value range of $1.53 to $2.10.
Technical Outlook: Technically, MIST is in a downtrend. Immediate support is located at $1.76, while resistance sits at $2.02.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.50 (+238.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MIST is in a downtrend. Immediate support is located at $1.76, while resistance sits at $2.02.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.50 (+238.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.53 -
$2.10
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 238.5% below Wall St target ($6.50)
Trading Range Analysis
30-Day Trading Range
$1.53 -
$2.10
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.77
Resistance Level
$2.02
Current Trend
Downtrend
Technical data as of
May 8, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.12
Wall Street Target
$6.50
(+238.5%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: May 10, 2026 12:21 PM ET
Data refreshes hourly during market hours. Next update: 1:21 PM
Data refreshes hourly during market hours. Next update: 1:21 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MIST showing a specific setup today?
Insider Activity (6 Months)
0
Buys
11
Sells
Net
INSIDERS SELLING
Recent Transactions
Joseph Oliveto
SELL
36500 shares
2026-04-16
David Bharucha
SELL
12245 shares
2026-01-26
Jeffrey Edward Nelson
SELL
12245 shares
2026-01-26
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 58 HOLD |
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 53 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$270 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 62 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 58 HOLD |
